Roivant

Revised Blueprint-VantAI deal turns focus to molecular glues

Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics.

Gabrielle Masson May 20, 2025 10:32am

Parachute over a mountain in Switzerland

Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders

Apr 25, 2025 8:30am

Immunovant narrows R&D focus as Roivant execs join C-suite

Apr 21, 2025 10:00am

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am

Big Pharma layoff rounds jump 281% in 2024

Jan 3, 2025 3:29pm

Roivant’s midstage asset fails to show benefit in lung disease

Dec 3, 2024 10:32am